Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization

  • Nicole V. Tolan
  • , Matthew D. Krasowski
  • , Patrick C. Mathias
  • , Joesph R. Wiencek
  • , Nikolina Babic
  • , Peter R. Chai
  • , Allison B. Chambliss
  • , Ibrahim Choucair
  • , Christiana A. Demetriou
  • , Timothy B. Erickson
  • , Matthew Feldhammer
  • , Deborah French
  • , Bryan D. Hayes
  • , Phillip Kang
  • , Joe M. El-Khoury
  • , Claire E. Knezevic
  • , Andrew Monte
  • , Robert D. Nerenz
  • , Anthony O. Okorodudu
  • , Stephen M. Roper
  • Alec Saitman, Vamsi Thiriveedhi, Sacha N. Uljon, Alexis Vest, Alison Woodworth, Min Yu, Stacy E.F. Melanson

Producción científica: Articlerevisión exhaustiva

9 Citas (Scopus)

Resumen

Background: Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-related emergency department visits in states with varying degrees of legalization. Methods: Seventeen healthcare institutions in fifteen states (California, Colorado, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Missouri, New Hampshire, Oregon, South Carolina, Tennessee, Texas, Washington) participated. Cannabinoid immunoassay results and cannabis-related International Classification of Diseases (ninth and tenth versions) codes were obtained for emergency department visits over a 3- to 8-year period during various stages of legalization: no state laws, decriminalized, medical approval before dispensaries, medical dispensaries available, recreational approval before dispensaries and recreational dispensaries available. Trends and monthly rates of cannabinoid immunoassay and cannabis-related International Classification of Diseases code positivity were determined during these legalization periods. Results: For most states, there was a significant increase in both cannabinoid immunoassay and International Classification of Diseases code positivity as legalization progressed; however, positivity rates differed. The availability of dispensaries may impact positivity in states with medical and/or recreational approval. In most states with no laws, there was a significant but smaller increase in cannabinoid immunoassay positivity rates. Conclusions: States may experience an increase in cannabis-related emergency department visits with progression toward marijuana legalization. The differences between states, including those in which no impact was seen, are likely multifactorial and include cultural norms, attitudes of local law enforcement, differing patient populations, legalization in surrounding states, availability of dispensaries, various ordering protocols in the emergency department, and the prevalence of non-regulated cannabis products.

Idioma originalEnglish
Páginas (desde-hasta)248-259
Número de páginas12
PublicaciónClinical Toxicology
Volumen61
N.º4
DOI
EstadoPublished - 2023

Nota bibliográfica

Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.

Financiación

The authors reported there is no funding associated with the work featured in this article. The authors acknowledge Dylan Calhoun and Caroline K. Tayler from Data Analytics at Dartmouth Hitchcock Medical Center and Vanderbilt University Medical Center, respectively, who provided the data from their state for analysis. The authors also acknowledge Tolumofe Terebo for her help with the initial data retrieval and secured data storage.

Financiadores
Dylan Calhoun

    ASJC Scopus subject areas

    • Toxicology

    Huella

    Profundice en los temas de investigación de 'Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization'. En conjunto forman una huella única.

    Citar esto